MedTrace Logo

Retinal Abnormalities as Biomarker of Disease Progression and Early Diagnosis of Parkinson Disease

NCT02640339 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 166

Last updated 2020-12-02

No results posted yet for this study

Summary

* To determine whether retinal abnormalities, as measured by high definition optical coherence tomography (HD-OCT) and visual electrophysiology techniques can be used as a clinical biomarker to monitor disease progression overtime in patients with Parkinson disease.
* To establish whether these measures can be used to identify patients with PD in the premotor phase.
* To define the rate of progression of retinal abnormalities in PD (both in the motor and premotor stages) for potential use as a clinical outcome measure

Conditions

  • Parkinson Disease
  • Multiple System Atrophy
  • REM Sleep Behavior Disorder
  • Pure Autonomic Failure
  • Dementia With Lewy Bodies

Sponsors & Collaborators

  • Michael J. Fox Foundation for Parkinson's Research

    collaborator OTHER

  • NYU Langone Health

    lead OTHER

Principal Investigators

  • Horacio C Kaufmann, MD · NYU Langone Health

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2020-09-30
Completion
2020-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02640339 on ClinicalTrials.gov